Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Identifying Chronic Kidney Disease (CKD)
Advantages and Pitfalls of the Current Classification System
Risk Factors
Costs of CKD
End of Life
Mark D. Purcell DO Nephrology/Internal Medicine
Carolina Nephrology, PA
203 Mills Avenue
Greenville, SC 29605
(864) 271-1844
Objectives
Identify patients with chronic kidney disease (CKD), the staging of CKD, and recognize the challenges and limitations with the current classification system.
Identify risk factors in the development and progression of CKD as well as associated complications including death.
Recognize that early recognition of progressive CKD, with appropriate management and early referral, should lead to both clinical and economic benefits.
Case 56 y/o white female with hx of DM presents as a new patient to your
office
Vitals: BP: 165/102 HR: 80
PE/ROS otherwise unremarkable
UA reveals proteinuria
Creatinine of 1.2 mg/dL
Does this patient have CKD ? ?
How severely compromised is her renal function?
Is creatinine an acceptable marker
Etiology: DM vs. HTN
Objectives
Identify patients with chronic kidney disease (CKD), the staging of CKD, and recognize the challenges and limitations with the current classification system.
Identify risk factors in the development and progression of CKD as well as associated complications including death.
Recognize that early recognition of progressive CKD, with appropriate management and early referral, should lead to both clinical and economic benefits.
Vol 1, CKD, Ch i
Data Source: Medicare 5 percent sample. This graphic also appears as Figure 2.1.
Figure i.4 Temporal trends in CKD prevalence, overall and by CKD stage, among Medicare patients age 65+, 2000-2012
http://www.usrds.org/2014
Definition Of CKD
There are two independent criteria for CKD:
Kidney damage for ≥ 3 months structural or functional abnormalities of the kidney, with or without
decreased GFR, manifest by either:
pathological abnormalities; or
markers of kidney damage, including abnormalities in the composition of the blood or urine; or abnormalities in imaging tests.
GFR < 60 mL/min/1.73m2 for ≥ 3 months, with or without kidney damage.
Pathologic Abnormalities
By Radiology (US, CT, MR, etc.) Multiple cysts consistent with polycystic kidney disease
(PKD)
Extensive scarring
Small kidneys--but be careful of the term “medical renal disease”
Renal masses or cysts that are not simple should be referred to a urologist
By Histology--i.e., renal biopsy
Markers of “Kidney Damage”
Electrolyte and other abnormalities due to tubular disorders
Urine sediment abnormalities Proteinuria
Microalbuminuria
Hematuria (especially when seen with proteinuria) Isolated hematuria has a long differential: infection, stone, malignancy,
etc.
Casts (especially with cellular elements)
History of kidney transplantation
YES NO
Risk Factor Reduction • Determine Stage of CKD
• Determine underlying cause
• Identify risk factors for
progression
• Identify comorbidities
Patient meets definition of Chronic Kidney Disease?
Creatinine Vs GFR Why Estimate GFR From SCr ?
Serum Creatinine Alone Is a Poor Indicator
of Kidney Function
Why Estimate GFR From SCr, Instead
of Using SCr for Kidney Function?
Age Gender Race SCr (mg/dL) eGFR (mL/min/1.73 m2)
CKD stage
20 M B 1.3 91 1*
20 M W 1.3 75 2*
55 M W 1.3 61 2*
55 F B 1.3 55 3
55 F W 1.3 46 3
GFR calculator available at: www.kidney.org/index.cfm?index=professionals.
B = black; †W = all ethnic groups other than black.
* If pathological abnormalities or markers of kidney damage
Glomerular Filtration Rate (GFR)
GFR is the best overall index of kidney function in health and disease. Normal GFR varies according to age, sex, and
body size.
Young adults ≈ 120-130 mL/min/1.73 m 2 and declines with age.
GFR can be estimated from prediction equations (eGFR) MDRD Study (recommended by K/DOQI)
Cockcroft-Gault formula
Stage Description GFR Action
At increased risk ≥ 90 (with CKD
risk factors)
Screening, CKD risk reduction
1 Kidney damage with
normal or ↓ GFR
≥ 90 Diagnosis and treatment, Treatment of co-
morbid conditions, Slowing progression,
CVD risk reduction
2 Kidney damage with
mild ↓ GFR
60-89 Estimating progression
3 Moderate ↓ GFR 30-59 Evaluating and treating complications
4 Severe ↓ GFR
15-29 Preparation for kidney replacement
therapy
5 Kidney Failure <15 (or dialysis) Replacement (if uremic)
Stages of Chronic Kidney Disease (CKD)
Adapted from NKF K/DOQI
Vol 1, CKD, Ch i
Data Source: National Health and Nutrition Examination Survey (NHANES), 1988–1994, 1999-2004 & 2007–2012 participants age 20 & older. Abbreviations: CKD, chronic kidney disease. This graphic also appears as Figure 1.11.
Figure i.3 NHANES participants with CKD aware of their kidney disease, 1999-2010
http://www.usrds.org/2014
MDRD
eGFR (mL/min/1.73 m 2) = 186 x (Creat/88.4)-1.154 x (Age)– 0.203 x (0.742 if female) x (1.210 if AA)
Limitations The MDRD Study equation is less accurate at GFR estimates greater
than 60 mL/min/1.73 m2
At levels of estimated GFR less than 60 mL/min/1.73 m2, the equation is accurate for most persons of average body size and muscle mass
The MDRD Study equation has not been validated in children (age < 18 years)
pregnant women
elderly (age > 70 years)
racial or ethnic subgroups other than Caucasians and African Americans
individuals with normal kidney function who are at increased risk for CKD
Lab Results From 1995
Fast Forward to 2010
45 y/o female with cirrhosis
24 hour urine collection: 45 y/o with cirrhosis
By MDRD eGFR 53 mL/min/1.73 m2 based on serum creatinine of 1.11 mg/dL
Definition of Proteinuria
Nephrotic Range ≥ 3.5 g/day
Overt Proteinuria > 300 mg/day
Microalbuminuria 30-300 mg/day
Orthostatic Proteinuria
Objectives
Identify patients with chronic kidney disease (CKD), the staging of CKD, and recognize the challenges and limitations with the current classification system.
Identify risk factors in the development and progression of CKD as well as associated complications including death.
Recognize that early recognition of progressive CKD, with appropriate management and early referral, should lead to both clinical and economic benefits.
Causes of Kidney Failure
37%
19%4%
16%
24%
Diabetes
Hypertension
Glomerulonephritis
Polycystic Kidney
Disease
Other
Diabetes is the Predominant Cause of Kidney Failure
US Renal Data System 2005 Annual Data Report
Patient Characteristics Associated with Increased
Rate of GFR Decline
Nonmodifiable
African American race
Female gender
Old age
Lower baseline level of
kidney function
Modifiable
Higher level of
proteinuria
Higher BP
Poor glycemic control
Smoking
2nd study out of Kaiser Permanente
Analyzed outcomes in
1,120,295 adults with CKD.
Median follow up 2.84 yrs.
Cardiovascular events
followed stepwise
progression
0
5
10
15
20
25
30
35
40
>60 45-59
30--44
15-29
<15
Death from anycause
Cardiovasculardisease
•Most patients died of cardiovascular
causes
2004,351:1296-1305
Majority of CKD patients died before
ending up on dialysis.
Vol 1, CKD, Ch i
Data source: Medicare 5 percent sample. January 1 point prevalent Medicare patients age 66 and older. Adj: age/sex/race/prior year hospitalization/comorbidities. Ref: 2012 patients. Abbreviations: CKD, chronic kidney disease. This graphic also appears as Figure 3.1.
Figure i.7 Unadjusted and adjusted all-cause mortality rates (per 1,000 patient years at risk) for Medicare patients aged 66 and older, by CKD status and year, 1995-2012
(A) Unadjusted (B) Adjusted
http://www.usrds.org/2014
Objectives
Identify patients with chronic kidney disease (CKD), the staging of CKD, and recognize the challenges and limitations with the current classification system.
Identify risk factors in the development and progression of CKD as well as associated complications including death.
Recognize that early recognition of progressive CKD, with appropriate management and early referral, should lead to both clinical and economic benefits.
CKD
death
Stages in Progression of Chronic Kidney Disease
and Therapeutic Strategies
Complications
Screening
for CKD
risk factors
CKD risk
reduction;
Screening for
CKD
Diagnosis
& treatment;
Treat
comorbid
conditions;
Slow
progression
Estimate
progression;
Treat
complications;
Prepare for
replacement
Replacement
by dialysis
& transplant
Normal Increased
risk
Kidney
failure Damage GFR
AJKD 2002: 39(2)
Stage 1-2 Stage 3 Stage 4 Stage 5
GFR >60 30-59 15-29 <15
BP control, ACEI/ARB
Glycemic control
CVD risk reduction: Dyslipidemia
management, Tobacco cessation
Avoid NSAIDS/Contrast
Anemia
Nutrition
Renal bone disease
Vascular access & Transplantation
CKD Intervention: Clinical Action Plan
Preparation for Renal Replacement
Therapy
Pre-emptive transplantation
ESRD options/education
ESRD outcomes
Hemodialysis
Peritoneal Dialysis
Case 56 y/o white female with hx of DM presents as a new patient to your
office
Vitals: BP: 165/102 HR: 80
PE/ROS otherwise unremarkable
UA reveals proteinuria
Creatinine of 1.2 mg/dL
Does this patient have CKD ? ?
How severely compromised is her renal function?
Is creatinine an acceptable marker
Etiology: DM vs. HTN
Case : Suggestive findings
56 yr old W female hx DM, uncontrolled HTN with a cr 1.2 mg/dL and dipstick positive for 1 + proteinuria
Suggestive of Diabetic Nephropathy: evidence of micro-
vascular complications like retinopathy, neuropathy, large kidneys, macroalbuminuria or microalbuminuria plus retinopathy or > 10 yr of type 1 diabetes with microalbuminuria
Suggestive of Hypertensive Nephrosclerosis: long history of hypertension with retinopathy, left ventricular hypertrophy, small kidneys, slowly progressive renal insufficiency, gradually increasing non-nephrotic proteinuria
* Referring clinicians may wish to discuss with their nephrology service depending on local arrangements regarding monitoring or referring.
Source: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of CKD. Volume 3, Issue 1, January 2013.
Reproduced with permission of Kidney Disease Improving Global Outcomes (KDIGO) / www.kdigo.org
COMPLIMENTS OF:
Referral Decision Making By GFR and Albuminuria
Early vs. Late Referral: Consequences and Benefits
Consequences of late referral
Anemia and bone disease
Severe hypertension and fluid overload
Low prevalence of permanent access
Higher initial hospitalization rate
Higher 1-year mortality
Less patient choice of dialysis modality choice
Worse psychosocial adjustment
Benefits of early referral
Delay need to initiate dialysis
Higher proportion of permanent access
Greater choice of treatment options
Reduced need for urgent dialysis
Reduced hospital LOS and cost
Improved nutritional status
Better management of CVD and comorbid conditions
Higher patient survival
Kidney Wellness Center
Components of Carolina Nephrology Kidney Wellness Center
Disease Monitoring
Integration with other chronic disease management programs including DM, HTN, and CHF
Rx management and dietary advice
Anemia Management
Vaccination programs
Information and psychosocial support
Renal replacement therapy education (HD, PD, and transplant)
Advanced care planning and end-of-life care (where appropriate)
Overall expenditures on Parts A and B services for the Medicare population age 65+ and for those with CKD, by year, 1993-2012
Vol 1, CKD, Ch 6
Data source: Medicare 5 percent sample. Abbreviations: CKD, chronic kidney disease.
http://www.usrds.org/2014
Summary
Optimal Management of the Rising Creatinine
Screen “Spot” urine albumin
microalbumin to creatinine ratio
Estimate GFR from serum creatinine using the MDRD prediction equation
Delay Progression
BP control ACE-I/ARB Blood sugar control ? Protein restriction in
advanced disease
Treat Comorbidities
Anemia
Mineral and Bone Disorder
Hyperlipidemia
Cardiovascular disease
Nutrition, Acidosis
Preparation for renal replacement
Questions/Comments
Mark D. Purcell DO Nephrology/Internal Medicine
Carolina Nephrology, PA
203 Mills Avenue
Greenville, SC 29605
(864) 271-1844